Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024)

Ginkgo Bioworks Holdings (DNA) posted Asset Writedowns and Impairment of $47.9 million for Q2 2024, down 60.58% on a QoQ basis from $121.4 million in Q4 2023, and up 431.7% year-over-year from $9.0 million in Q3 2023.

Ginkgo Bioworks Holdings (DNA) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends

Ginkgo Bioworks Holdings' Asset Writedowns and Impairment history runs 2 years deep, the most recent figure standing at $47.9 million for Q2 2024.

  • Quarterly Asset Writedowns and Impairment rose 431.7% year-over-year to $47.9 million in Q2 2024, while the trailing twelve-month figure through Sep 2025 was $47.9 million (down 83.01% YoY) and the FY2024 annual result came in at $4.8 million, down 96.03% from the prior year.
  • Asset Writedowns and Impairment was $47.9 million for Q2 2024 at Ginkgo Bioworks Holdings, down from $121.4 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $121.4 million in Q4 2023 and bottomed at $9.0 million in Q2 2023.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,071.81 Bn -
2 Nanobiotix 1,925.70 Bn 1,925.64 Bn -
3 Akari Therapeutics 1,062.88 Bn 1,062.88 Bn -
4 BeOne Medicines 469.09 Bn 464.29 Bn 1.35 Bn
5 Vertex Pharmaceuticals 123.09 Bn 115.84 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.32 Bn 61.57 Bn 3.31 Bn
7 Belite Bio 63.36 Bn 63.36 Bn -
8 Argenx Se 55.90 Bn 50.71 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.69 Bn 34.68 Bn 959.66 Mn
10 Ginkgo Bioworks Holdings 447.02 Mn 303.16 Mn 16.38 Mn

Historic Data

Download Data
DateValue
Jun 30, 2024 47.86 Mn
Jun 30, 2024 47.86 Mn
Dec 31, 2023 121.40 Mn
Dec 31, 2023 121.40 Mn
Sep 30, 2023 112.40 Mn
Sep 30, 2023 112.40 Mn
Jun 30, 2023 9.00 Mn
Jun 30, 2023 9.00 Mn